Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.0652W HIGH $17.43
Volume
432.29 K
Value Traded
1.61 M
Short % Float
16.27%
Days to Cover
4.6
+4.15%Week
-23.45%1 Month
-47.28%3 Month
-27.05%6 Month
-90.28%5 Year
-99.73%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
99.33 M
EPS (TTM)
-8.18
P/E Ratio
-
Ent. Value
-55.97 M
Total Shares
13.64 M
Float Shares
12.76 M
Insiders
6.52%
Institutions
74.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
IMUX Catalyst Timeline
Dated clinical, regulatory and corporate events for Immunic, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immunic, Inc.
554Total events
16Upcoming
125Tier-1 (high impact)
2018 to 2031Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationIMU-838Presentation
Poster P1273: Nurr1-dependent neuronal survival and neuroprotective effects of vidofludimus calcium
multiple sclerosissource ↗
●Poster PresentationIMU-838Presentation
Poster P0387: CALLIPER OLE disability outcomes with vidofludimus calcium
progressive multiple sclerosissource ↗
▲Poster PresentationIMU-838Presentation
Additional Phase 2 CALLIPER data presented at CMSC Annual Meeting
progressive multiple sclerosissource ↗
◆Poster PresentationIMU-856Presentation
EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026: Discovery of IMU-856 poster
gastrointestinal diseasesource ↗
◆Oral PresentationPresentation
H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit fireside chat
◆Poster PresentationIMU-838Presentation
Late-breaking poster: Novel Unified Statistical Analyses for Confirmed Disability Changes in MS
progressive multiple sclerosissource ↗
◆Late-BreakerIMU-838Presentation
Late-breaking poster presenting novel unified endpoint Confirmed Disability Change (CDC) at CMSC 2026
progressive multiple sclerosissource ↗
▲Poster PresentationIMU-838Presentation
Poster on safety and tolerability data from CALLIPER trial at CMSC 2026
progressive multiple sclerosissource ↗
●Management ChangeCorporate
Michael W. Bonney appointed Chair of Board effective May 16, 2026
◆Oral PresentationPresentation
Immunic management to attend Bio€quity Europe and host one-on-one meetings
◆Oral PresentationIMU-838Presentation
Presentation at 8th Annual Neuroimmunology Drug Development Summit highlighting vidofludimus calcium
multiple sclerosissource ↗
◆Trial CompletionIMU-838Trial
Completion of twin phase 3 ENSURE trials in relapsing MS expected in Q2 2026 and H2 2026
relapsing multiple sclerosissource ↗
◆Topline ReadoutIMU-838Clinical Data
Top-line readout of first ENSURE trial
relapsing multiple sclerosissource ↗
◆Oral PresentationPresentation
Participation at Leerink Partners Global Healthcare Conference
▲Patent GrantedIMU-838IP / Competition
European Patent Office granted key patent EP3713554 covering label-relevant dosing regimens of vidofludimus calcium
▲Patent GrantedIMU-838IP / Competition
Grant of key European patent for dosing regimens of vidofludimus calcium
multiple sclerosissource ↗
▲Equity OfferingCorporate
Oversubscribed private placement financing closed earlier this year
▲Equity OfferingCorporate
Completed oversubscribed private placement raising $200 million upfront, with potential for additional $200 million
▼Equity OfferingCorporate
Closing of oversubscribed private placement financing with upfront proceeds of USD 200 million
▲Partnership / LicenseIMU-838Corporate
Purchase and sale agreement for 5% royalty on future net sales in exchange for cancellation of Series B Warrants
▲Poster PresentationIMU-838Presentation
Additional Phase 2 CALLIPER MRI data and EBV-specific T-cell receptor data presented at ACTRIMS Forum 2026
progressive multiple sclerosissource ↗
●Poster PresentationIMU-838Presentation
Presented additional data from phase 2 CALLIPER trial at ACTRIMS Forum 2026
progressive multiple sclerosissource ↗
●Oral PresentationPresentation
One-on-one meetings at 44th Annual J.P. Morgan Healthcare Conference
◆Oral PresentationPresentation
Immunic CEO to participate in fireside chat at Evercore ISI Healthcare Conference
◆Oral PresentationPresentation
Participation in industry and investor conferences in November
◆Oral PresentationPresentation
Virtual fireside chat at H.C. Wainwright HCW @ Home with Immunic
◆Oral PresentationPresentation
Immunic CEO panel participation at Roth Healthcare Opportunities Conference
◆Poster PresentationIMU-838Presentation
Poster presentation of vidofludimus calcium neuroprotection preclinical data at ISNI 2025
multiple sclerosissource ↗
◆Oral PresentationIMU-856Presentation
Oral presentation of IMU-856 Phase 1 data on gut hormone levels in celiac disease at UEGW 2025
celiac diseasesource ↗
◆Poster PresentationIMU-856Presentation
ePoster presentation of IMU-856 biomarkers of extracellular matrix remodeling at UEGW 2025
celiac diseasesource ↗
◆Poster PresentationIMU-838Presentation
Poster on 144-week analysis of confirmed disability worsening from open-label extension of Phase 2 EMPhASIS trial at ECTRIMS 2025
relapsing-remitting multiple sclerosissource ↗
▲Oral PresentationIMU-838Presentation
Oral presentation of CALLIPER trial data at ECTRIMS 2025
progressive multiple sclerosissource ↗
▲Poster PresentationIMU-838Presentation
Late-breaking poster on PPMS subpopulation of CALLIPER trial at ECTRIMS 2025
progressive multiple sclerosissource ↗
Past FDA Catalysts and PDUFA Decisions
How IMUX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-22 | vidofludimus calcium (IMU-838) | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 14%
Micro Cap(rank 93 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IMU-838 Small moleculeNCT03846219 | Multiple Sclerosis, Relapsing-Remitting | Phase 3 | ACTIVE NOT_RECRUITING | 1,310 | Dec 1, 2029 | ||||||
| IMU-838 Small moleculeNCT05134441 | Multiple Sclerosis | Phase 3 | ACTIVE NOT_RECRUITING | 1,121 | Sep 1, 2033 | ||||||
| IMU-838 Small moleculeCompletedNCT04379271 | COVID-19 | Phase 2 | COMPLETED | 234 | Feb 23, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every IMUX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| vidofludimus calcium | progressive multiple sclerosis | Phase 2 | 2026-10-21 | Only 6.5% of patients discontinued through the January 27, 2026 data cutoffRead More | Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Skerjanec SimonaDirector | Grant/Award | 25,370 25,370 held | $0.00 | 07/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IMUX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 0.3 % | 11.76 M | 765.29 K | -90% ( -6.89 M) |
IMUX Institutional Ownership Trends
IMUX Short Interest
Shares sold short, counted twice a month.
16.27%
Short % of Float
of tradable shares sold short
2.1M
Shares Sold Short
+15.7% vs prior count
4.6 Moderate
Days to Cover
trading days of normal volume to buy every short share back
455.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMUX ranks across every disease it competes in
Competitive Position is a premium feature
See how IMUX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMUX News
-IMUX
Oct 21, 2026Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Immunic presented new data for vidofludimus calcium at MSToronto2026, highlighting positive outcomes from the Phase 2 CALLIPER trial. The open-label extension showed sustained disability improvements, while preclinical studies indicated neuroprotective effects. Additionally, reductions in EBV-specific T-cell signatures were associated with cognitive performance enhancements. The findings support the upcoming Phase 3 program for progressive MS.
Read more →-IMUX
Oct 19, 2026Immunic Appoints Jaa Roberson as Chief People Officer
Immunic, Inc. has appointed Jaa Roberson as Chief People Officer to enhance its leadership team as it prepares for pivotal Phase 3 clinical trials for its MS treatment. Roberson will focus on attracting specialized talent and building organizational capabilities necessary for potential commercialization. This strategic move aligns with Immunic's goal of becoming a leading organization in multiple sclerosis therapies.
Read more →-IMUX
Oct 13, 2026▼ -13.3%on this news
Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunic, Inc. announced the granting of inducement equity grants for 12,900 shares to three new employees as part of its 2026 Inducement Equity Compensation Plan. This move is aligned with NASDAQ Listing Rule 5635(c)(4) and aims to enhance employee retention. The company is also progressing with its lead therapy, vidofludimus calcium, in Phase 3 trials for multiple sclerosis.
Read more →-IMUX
Oct 7, 2026Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Immunic, Inc. announced the acceptance of four abstracts for presentation at MSToronto2026, showcasing new clinical, biomarker, and preclinical data on vidofludimus calcium. The findings highlight its potential benefits in multiple sclerosis, particularly in long-term disability outcomes and neuroprotective effects. The presentations will occur during the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto.
Read more →-IMUX
Sep 2, 2026Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
Immunic, Inc. will host a virtual R&D day on September 9, 2026, to discuss its investigational therapy, vidofludimus calcium, for relapsing multiple sclerosis. The event will feature insights from key opinion leaders in the field, ahead of the anticipated top-line data from the Phase 3 ENSURE trials. This initiative aims to address unmet needs in MS treatment.
Read more →-IMUX
Sep 1, 2026▼ -7.7%on this newsshared move
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
Immunic, Inc. has appointed Chitrang Davé as Chief Data and Digital Officer to enhance its data strategy and support the commercialization of vidofludimus calcium. This new role aims to prepare for a potential New Drug Application (NDA) submission as the company transitions from clinical development to commercial readiness. Davé's extensive experience in data and analytics will be crucial during this pivotal phase.
Read more →-IMUX
Aug 11, 2026▲ +9.8%on this news
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Immunic, Inc. reported its second quarter 2026 financial results, highlighting key executive appointments and advancements in its clinical programs. The company is on track to deliver top-line data from its Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis by the end of 2026. Preparations for a Phase 3 trial in progressive MS are also underway, with significant financial backing following a successful private placement.
Read more →-IMUX
Aug 10, 2026▲ +9.8%on this newsshared move
Immunic Appoints Elena Ridloff to Board of Directors
Immunic, Inc. has appointed Elena Ridloff to its Board of Directors, effective August 6, 2026. Ridloff, a seasoned executive with over two decades in the biopharmaceutical industry, will contribute her expertise as the company prepares for significant clinical milestones, including the Phase 3 ENSURE trial readout for vidofludimus calcium in relapsing multiple sclerosis. Her appointment is seen as a strategic move to enhance the company's growth trajectory.
Read more →-IMUX
Jul 9, 2026Immunic to Participate in Investor Conferences in July
Immunic, Inc. announced its participation in several investor conferences in July 2026. Key executives will engage in one-on-one meetings and discussions at the Leerink Partners Therapeutics Forum, B. Riley Securities Mind, Muscle & Vision Summit, and LifeSci Capital SF Biotech Forum. The company is also progressing its lead therapy, vidofludimus calcium, in Phase 3 clinical trials for relapsing multiple sclerosis.
Read more →-IMUX
Jun 10, 2026Immunic to Participate in Investor, Industry and Scientific Conferences in June
Immunic, Inc. announced its participation in several key conferences in June 2026, including the H.C. Wainwright Neuro Perspectives Summit and the BIO International Convention. The company's management will engage in discussions and presentations about their ongoing development programs, particularly focusing on their lead candidate, vidofludimus calcium, which is in phase 3 trials for multiple sclerosis. This involvement highlights Immunic's commitment to advancing its therapeutic pipeline and fostering investor relations.
Read more →-IMUX
May 28, 2026▲ +6.9%on this news
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic, Inc. presented new data from its Phase 2 CALLIPER trial for vidofludimus calcium at the CMSC Annual Meeting 2026. The findings highlight a novel statistical approach to assess disability changes in progressive multiple sclerosis, showing favorable safety and tolerability. Patient-reported outcomes indicated no adverse mood effects, reinforcing the drug's potential in treating the condition.
Read more →-IMUX
May 27, 2026▲ +7.9%on this newsshared move
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
Immunic, Inc. has appointed Erik Lundgren as its new CEO, effective June 1, 2026. Lundgren, with extensive experience in the biopharmaceutical industry, will lead the company as it advances its lead asset, vidofludimus calcium, through late-stage clinical trials for multiple sclerosis. His prior success with Ocrevus® is expected to be instrumental in Immunic's transition to a commercial-stage company.
Read more →-IMUX
May 19, 2026Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Immunic, Inc. has appointed Michael W. Bonney as Chair of the Board of Directors, effective May 16, 2026. Bonney, a seasoned biopharmaceutical executive, has over 30 years of experience, including significant roles at Biogen and Cubist Pharmaceuticals. His expertise in multiple sclerosis and commercialization will be pivotal as Immunic advances its lead program, vidofludimus calcium, through clinical trials.
Read more →-IMUX
May 13, 2026▲ +8.8%on this news
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Immunic, Inc. reported its Q1 2026 financial results, highlighting the appointment of Michael A. Panzara as Chief Medical Officer and the ongoing Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis. The company raised $200 million in a private placement, with expectations for top-line data by the end of 2026. Despite a net loss of $32.6 million, the company is positioned for potential commercialization and further development in multiple sclerosis treatments.
Read more →-IMUX
Apr 30, 2026Immunic to Participate in Investor and Medical Conferences in May
Immunic, Inc. announced its participation in several investor and medical conferences in May 2026, including the Bio€quity Europe and the Consortium of Multiple Sclerosis Centers Annual Meeting. The company will present late-breaking and additional poster presentations showcasing their research on vidofludimus calcium, a treatment for multiple sclerosis. This engagement emphasizes Immunic's commitment to advancing therapies for neurologic diseases.
Read more →-IMUX
Apr 28, 2026▲ +7.7%on this newsshared move
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
Immunic, Inc. has appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer. Dr. Panzara, with over 25 years of experience in neurology, will lead the company's development organization and is expected to play a key role in advancing the clinical development of vidofludimus calcium. His appointment comes as Immunic prepares for pivotal trials in multiple sclerosis.
Read more →-IMUX
Apr 23, 2026Immunic, Inc. Announces 1-for-10 Reverse Stock Split
Immunic, Inc. announced a 1-for-10 reverse stock split effective April 27, 2026, to meet contractual obligations. The decision was approved by stockholders on April 14, 2026. This action will reduce the number of outstanding shares from approximately 136 million to 13.6 million while maintaining the same ownership percentages for stockholders.
Read more →-IMUX
Apr 9, 2026▲ +8.4%on this news
Immunic to Participate in Scientific and Medical Conferences in April
Immunic, Inc. announced its participation in key scientific and medical conferences in April 2026, including the Neuroimmunology Drug Development Summit and the American Academy of Neurology Annual Meeting. At these events, the Chief Scientific Officer will present findings on their lead asset, vidofludimus calcium, which is in phase 3 trials for multiple sclerosis. The company aims to highlight its unique therapeutic approach combining neuroprotective and anti-inflammatory properties.
Read more →-IMUX
Apr 1, 2026Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
Immunic, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement. The company achieved this as its stock price remained above $1.00 for at least 20 consecutive business days. This compliance is crucial for its continued listing on the Nasdaq Capital Market. Immunic is focused on developing therapies for neurologic diseases, with its lead program currently in phase 3 trials.
Read more →About Immunic, Inc.
Headquarters1200 AVENUE OF THE AMERICAS, NEW YORK, X1, 10036
BIOPHARMAWATCH ELITE PLUS
Trade the next IMUX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime